XMIL
LBM
Market cap210mUSD
Aug 29, Last price
9.95EUR
Name
Labomar SpA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Labomar S.p.A., an Italian company established in 1998 and headquartered in Istrana, specializes in the global research, development, production, and commercialization of a wide range of health-focused products. Its market presence spans Italy, France, Poland, Spain, North America, and other international regions. The company's comprehensive product line includes food supplements addressing diverse therapeutic needs such as immune system support, digestive health, respiratory conditions (cough and cold), neurological wellness, oncology support, vision care, sports nutrition, dermatological health, 'inside beauty' applications, cardiovascular health, orthopedic issues, pediatrics, detoxification, and metabolic syndrome management. This segment also features essential vitamins, minerals, and antioxidants. Labomar further manufactures medical devices for use in gynecology, respiratory and gastrointestinal ailments, wound healing, metabolic disorders, proctology, detoxification, and oral wound care. Additionally, it provides foods for special medical purposes, catering to needs in gastroenterology, endocrinology, and dysphagia. Within its cosmetics division, the company develops products for internal beauty, skin cleansing, general skincare, haircare, oral wound care, sun protection, and specific dermatological conditions including acne rosacea, acne, atopic dermatitis, and bruises. Probiotic food supplements are also part of its offerings. Beyond its proprietary brands, Labomar extends its expertise through contract development and manufacturing services for other companies. Its products are available in various formats, including tablets, capsules, liquids, powders, and semi-solids. A significant commercial partnership with Bayer involves Labomar in the development and production of various pharmaceutical formulations in different flavors and forms.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||